146 related articles for article (PubMed ID: 20798777)
1. Oral microencapsulated live Saccharomyces cerevisiae cells for use in renal failure uremia: preparation and in vivo analysis.
Coussa R; Martoni C; Bhathena J; Urbanska AM; Prakash S
J Biomed Biotechnol; 2010; 2010():. PubMed ID: 20798777
[TBL] [Abstract][Full Text] [Related]
2. Microencapsulated genetically engineered live E. coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats.
Prakash S; Chang TM
Nat Med; 1996 Aug; 2(8):883-7. PubMed ID: 8705857
[TBL] [Abstract][Full Text] [Related]
3. Microencapsulated Saccharomyces cerevisiae column bioreactor for potential use in renal failure uremia.
Coussa RG; Shah S; Jain P; Martoni C; Bhathena J; Malhotra M; Prakash S
Artif Cells Blood Substit Immobil Biotechnol; 2012 Feb; 40(1-2):103-12. PubMed ID: 22288841
[TBL] [Abstract][Full Text] [Related]
4. In-vitro analysis of APA microcapsules for oral delivery of live bacterial cells.
Chen H; Ouyang W; Jones M; Haque T; Lawuyi B; Prakash S
J Microencapsul; 2005 Aug; 22(5):539-47. PubMed ID: 16361197
[TBL] [Abstract][Full Text] [Related]
5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
6. Does the adequacy parameter Kt/V(urea) reflect uremic toxin concentrations in hemodialysis patients?
Eloot S; Van Biesen W; Glorieux G; Neirynck N; Dhondt A; Vanholder R
PLoS One; 2013; 8(11):e76838. PubMed ID: 24236005
[TBL] [Abstract][Full Text] [Related]
7. Oral administration of biochemically active microcapsules to treat uremia: new insights into an old approach.
O'Loughlin JA; Bruder JM; Lysaght MJ
J Biomater Sci Polym Ed; 2004; 15(11):1447-61. PubMed ID: 15648574
[TBL] [Abstract][Full Text] [Related]
8. Utilization of adsorbing materials for uremic blood purification.
Denti E
Biomater Med Devices Artif Organs; 1974; 2(3):295-300. PubMed ID: 4458819
[No Abstract] [Full Text] [Related]
9. Optimization of 100 μm alginate-poly-L-lysine-alginate capsules for intravitreous administration.
Santos E; Orive G; Calvo A; Catena R; Fernández-Robredo P; Layana AG; Hernández RM; Pedraz JL
J Control Release; 2012 Mar; 158(3):443-50. PubMed ID: 21971294
[TBL] [Abstract][Full Text] [Related]
10. Plasma OLC is elevated in mild experimental uremia but is not associated with hypertension.
Harwood S; Mullen AM; McMahon AC; Dawnay A
Am J Hypertens; 2001 Nov; 14(11 Pt 1):1112-5. PubMed ID: 11724209
[TBL] [Abstract][Full Text] [Related]
11. Removal of uremic waste metabolites from the intestinal tract by encapsulated carbon and oxidized starch.
Sparks RE; Mason NS; Meier PM; Litt MH; Lindan O
Trans Am Soc Artif Intern Organs; 1971; 17():229-38. PubMed ID: 5158097
[No Abstract] [Full Text] [Related]
12. A model of reversible uremia employing isogenic kidney transplantation in the rat. Reversibility of secondary hyperparathyroidism.
Lewin E; Colstrup H; Pless V; Ladefoged J; Olgaard K
Scand J Urol Nephrol; 1993; 27(1):115-20. PubMed ID: 8493458
[TBL] [Abstract][Full Text] [Related]
13. [Retention of medium sized molecules in uremic serum].
Dall'aglio P; Buzio C; Cambi V; Arisi L; Migone L
Proc Eur Dial Transplant Assoc; 1972; 9():409-16. PubMed ID: 4668919
[No Abstract] [Full Text] [Related]
14. Free and microencapsulated Lactobacillus and effects of metabolic induction on urea removal.
Chow KM; Liu ZC; Prakash S; Chang TM
Artif Cells Blood Substit Immobil Biotechnol; 2003 Nov; 31(4):425-34. PubMed ID: 14672417
[TBL] [Abstract][Full Text] [Related]
15. The clearance of unidentified uremic solutes (with molecular weight under 5 kDa) plays an important role in hemodialyzer selection.
Chen TS; Liou SY; Chang YL
Int Urol Nephrol; 2010 Jun; 42(2):465-70. PubMed ID: 19590973
[TBL] [Abstract][Full Text] [Related]
16. Continuous renal replacement therapy: does technique influence azotemic control?
Morimatsu H; Uchino S; Bellomo R; Ronco C
Ren Fail; 2002 Sep; 24(5):645-53. PubMed ID: 12380911
[TBL] [Abstract][Full Text] [Related]
17. Continuous enteral feeding in uremic rats.
Maniar S; Laouari D; Motel V; Kleinknecht C
Miner Electrolyte Metab; 1996; 22(1-3):88-91. PubMed ID: 8676834
[TBL] [Abstract][Full Text] [Related]
18. [Control by means of Computer control of the hematochemical picture in chronic uremic patients undergoing periodic hemodialysis treatment].
Novario PG; Pagliano B; Denti E; Segoloni G; Piccoli G; Vercellone A; Coppo R
Minerva Nefrol; 1974; 21(5):347-59. PubMed ID: 4467056
[No Abstract] [Full Text] [Related]
19. Degradation of low molecular weight uremic solutes by oral delivery of encapsulated enzymes.
O'Loughlin JA; Bruder JM; Lysaght MJ
ASAIO J; 2004; 50(3):253-60. PubMed ID: 15171478
[TBL] [Abstract][Full Text] [Related]
20. Studies on smaller (approximately 315 microM) microcapsules: IV. Feasibility and safety of intrahepatic implantations of small alginate poly-L-lysine microcapsules.
Leblond FA; Simard G; Henley N; Rocheleau B; Huet PM; Hallé JP
Cell Transplant; 1999; 8(3):327-37. PubMed ID: 10442745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
